These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1494 related articles for article (PubMed ID: 7820162)
1. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids. Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162 [TBL] [Abstract][Full Text] [Related]
2. A randomized comparative open study of the effects of two oral contraceptives, Triphasil and Ortho 7/7/7, on lipid metabolism. Kakis G; Powell M; Marshall A; Steiner G Contraception; 1993 Feb; 47(2):131-48. PubMed ID: 8449014 [TBL] [Abstract][Full Text] [Related]
3. Changes in coagulation and anticoagulation in women taking low-dose triphasic oral contraceptives: a controlled comparative 12-month clinical trial. Notelovitz M; Kitchens CS; Khan FY Am J Obstet Gynecol; 1992 Nov; 167(5):1255-61. PubMed ID: 1442974 [TBL] [Abstract][Full Text] [Related]
4. Effect of two oral contraceptives containing ethinyl estradiol and gestodene or norgestimate on different lipid and lipoprotein parameters. Wiegratz I; Jung-Hoffmann C; Gross W; Kuhl H Contraception; 1998 Aug; 58(2):83-91. PubMed ID: 9773262 [TBL] [Abstract][Full Text] [Related]
5. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. Godsland IF; Crook D; Simpson R; Proudler T; Felton C; Lees B; Anyaoku V; Devenport M; Wynn V N Engl J Med; 1990 Nov; 323(20):1375-81. PubMed ID: 2146499 [TBL] [Abstract][Full Text] [Related]
6. The effect of triphasic and biphasic oral contraceptive preparations on HDL-cholesterol and LDL-cholesterol in young women. Percival-Smith RK; Morrison BJ; Sizto R; Abercrombie B Contraception; 1987 Feb; 35(2):179-87. PubMed ID: 3595143 [TBL] [Abstract][Full Text] [Related]
7. Fasting plasma lipids, lipoproteins and apolipoproteins in Nigerian women using combined oral and progestin-only injectable contraceptives. Oyelola OO Contraception; 1993 May; 47(5):445-54. PubMed ID: 8513671 [TBL] [Abstract][Full Text] [Related]
8. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol. Wahl P; Walden C; Knopp R; Hoover J; Wallace R; Heiss G; Rifkind B N Engl J Med; 1983 Apr; 308(15):862-7. PubMed ID: 6572785 [TBL] [Abstract][Full Text] [Related]
9. A comparative study of the effects of a monophasic and a triphasic oral contraceptive containing ethinyl estradiol and levonorgestrel on lipid and lipoprotein metabolism. Loke DF; Ng CS; Samsioe G; Holck S; Ratnam SS Contraception; 1990 Nov; 42(5):535-54. PubMed ID: 2125546 [TBL] [Abstract][Full Text] [Related]
10. Comparative studies of the ethynyl estrogens used in oral contraceptives. VII. Effects with and without progestational agents on ultracentrifugally fractionated plasma lipoproteins in humans, baboons, and beagles. Goldzieher JW; Chenault CB; de la Peña A; Dozier TS; Kraemer DC Fertil Steril; 1978 Nov; 30(5):522-33. PubMed ID: 214353 [TBL] [Abstract][Full Text] [Related]
11. Serum lipid and lipoprotein changes induced by new oral contraceptives containing ethinylestradiol plus levonorgestrel or desogestrel. Gaspard UJ; Buret J; Gillain D; Romus MA; Lambotte R Contraception; 1985 Apr; 31(4):395-408. PubMed ID: 3159546 [TBL] [Abstract][Full Text] [Related]
12. Metabolic profile of six oral contraceptives containing norgestimate, gestodene, and desogestrel. Teichmann A Int J Fertil Menopausal Stud; 1995; 40 Suppl 2():98-104. PubMed ID: 8574257 [TBL] [Abstract][Full Text] [Related]
13. The clinical and biochemical effects of two combination oral contraceptive agents. Sapire KE; Berger GM; Maritz JS S Afr Med J; 1991 Apr; 79(7):376-9. PubMed ID: 1826569 [TBL] [Abstract][Full Text] [Related]
14. Effects of desogestrel and gestodene in low-dose oral contraceptive combinations on lipid and lipoprotein status. A randomized prospective study. Granata A; Sobbrio GA; D'Arrigo F; Barillari M; Curasì MP; Egitto M; Trimarchi F; Granese D; Pullè C Acta Eur Fertil; 1990; 21(3):143-6. PubMed ID: 2149913 [TBL] [Abstract][Full Text] [Related]
15. Relationships between blood pressure, oral contraceptive use and metabolic risk markers for cardiovascular disease. Godsland IF; Crook D; Devenport M; Wynn V Contraception; 1995 Sep; 52(3):143-9. PubMed ID: 7587185 [TBL] [Abstract][Full Text] [Related]
16. Effects of three low-dose oral contraceptive formulations on lipid metabolism. Bertolini S; Elicio N; Cordera R; Gapitanio GL; Montagna G; Croce S; Saturnino M; Balestreri R; De Cecco L Acta Obstet Gynecol Scand; 1987; 66(4):327-32. PubMed ID: 2962417 [TBL] [Abstract][Full Text] [Related]
17. Oral contraceptive and postmenopausal estrogen effects on lipoprotein triglyceride and cholesterol in an adult female population: relationships to estrogen and progestin potency. Knopp RH; Walden CE; Wahl PW; Hoover JJ; Warnick GR; Albers JJ; Ogilvie JT; Hazzard WR J Clin Endocrinol Metab; 1981 Dec; 53(6):1123-32. PubMed ID: 7298796 [TBL] [Abstract][Full Text] [Related]
18. Comparison of metabolic and clinical effects of four oral contraceptive formulations and a contraceptive vaginal ring. Roy S; Mishell DR; Gray G; Dozono-Takano R; Brenner PF; Eide I; de Quattro V; Shaw ST Am J Obstet Gynecol; 1980 Apr; 136(7):920-31. PubMed ID: 6767404 [TBL] [Abstract][Full Text] [Related]
19. Lipid and lipoprotein changes in women taking low-dose, triphasic oral contraceptives: a controlled, comparative, 12-month clinical trial. Notelovitz M; Feldman EB; Gillespy M; Gudat J Am J Obstet Gynecol; 1989 May; 160(5 Pt 2):1269-80. PubMed ID: 2655452 [TBL] [Abstract][Full Text] [Related]
20. Progestins and oral contraceptive-induced lipoprotein changes: a prospective study. Lipson A; Stoy DB; LaRosa JC; Muesing RA; Cleary PA; Miller VT; Gilbert PR; Stadel B Contraception; 1986 Aug; 34(2):121-34. PubMed ID: 3096633 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]